Promising preliminary results underscore validity of immunotherapy’s ability to cure cancer.
A new drug combination treats the underlying cause of cystic fibrosis (CF) in half of all people with this deadly disease.
Mild-to-moderate developmental delays that can accompany simple craniosynostosis can be overcome.
An aggressive transplant strategy plus exceptional post-transplant care equals better outcomes for even the most fragile children.
From redefining cancer treatment to revolutionizing autism research, our newest researchers are pursuing the next wave of pediatric breakthroughs.
Research institute adopts a manufacturing mentality to reduce the administrative burden of science.
Dr. Richard James’ team is gaining ground in its quest to understand drug resistance in patients with B-cell lymphoma.
Researchers show how a toxin made by GBS causes fetal injury and how that same toxin stimulates host immune cells to fight the bacteria.
Leading-edge technologies let researchers study the brain’s response to stimuli in ways not previously possible – and open paths to treating addiction.
Complementary expertise of three Seattle organizations creates a feeding device that could save infants in low-resource areas.
Academic Annual Report